BOSTON SCIENTIFIC CORP (BSX) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BSX - US1011371077 - Common Stock
90.03 USD
-3.71 (-3.96%)
90.07 USD
+0.04 (+0.04%)
We assign a fundamental rating of 6 out of 10 to BSX. BSX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. BSX scores excellent on profitability, but there are some minor concerns on its financial health. BSX is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
- In the past year BSX was profitable.
- In the past year BSX had a positive cash flow from operations.
- Of the past 5 years BSX 4 years were profitable.
- In the past 5 years BSX always reported a positive cash flow from operatings.
1.2 Ratios
- BSX's Return On Assets of 6.54% is amongst the best of the industry. BSX outperforms 86.49% of its industry peers.
- With an excellent Return On Equity value of 11.93%, BSX belongs to the best of the industry, outperforming 88.11% of the companies in the same industry.
- BSX's Return On Invested Capital of 8.09% is amongst the best of the industry. BSX outperforms 84.32% of its industry peers.
- BSX had an Average Return On Invested Capital over the past 3 years of 6.59%. This is below the industry average of 8.84%.
- The 3 year average ROIC (6.59%) for BSX is below the current ROIC(8.09%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.09% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
1.3 Margins
- The Profit Margin of BSX (14.42%) is better than 90.81% of its industry peers.
- In the last couple of years the Profit Margin of BSX has declined.
- BSX has a Operating Margin of 19.40%. This is amongst the best in the industry. BSX outperforms 92.43% of its industry peers.
- BSX's Operating Margin has been stable in the last couple of years.
- BSX's Gross Margin of 68.57% is fine compared to the rest of the industry. BSX outperforms 75.14% of its industry peers.
- BSX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
2. Health
2.1 Basic Checks
- BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- The number of shares outstanding for BSX has been increased compared to 1 year ago.
- Compared to 5 years ago, BSX has more shares outstanding
- The debt/assets ratio for BSX is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 5.13 indicates that BSX is not in any danger for bankruptcy at the moment.
- BSX's Altman-Z score of 5.13 is fine compared to the rest of the industry. BSX outperforms 77.30% of its industry peers.
- BSX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as BSX would need 3.03 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 3.03, BSX belongs to the top of the industry, outperforming 83.24% of the companies in the same industry.
- A Debt/Equity ratio of 0.48 indicates that BSX is not too dependend on debt financing.
- With a Debt to Equity ratio value of 0.48, BSX perfoms like the industry average, outperforming 43.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 5.13 |
ROIC/WACC0.84
WACC9.65%
2.3 Liquidity
- BSX has a Current Ratio of 1.51. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
- BSX has a worse Current ratio (1.51) than 73.51% of its industry peers.
- A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
- BSX has a worse Quick ratio (0.96) than 77.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
- BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.00%, which is quite impressive.
- Measured over the past years, BSX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.56% on average per year.
- BSX shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.62%.
- BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.30% yearly.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
- Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.06% on average per year.
- BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.60% yearly.
EPS Next Y22.13%
EPS Next 2Y18.12%
EPS Next 3Y16.5%
EPS Next 5Y15.06%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.6%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 30.52 indicates a quite expensive valuation of BSX.
- Compared to the rest of the industry, the Price/Earnings ratio of BSX indicates a somewhat cheap valuation: BSX is cheaper than 74.05% of the companies listed in the same industry.
- BSX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.54.
- With a Price/Forward Earnings ratio of 25.71, BSX can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, BSX is valued a bit cheaper than the industry average as 76.22% of the companies are valued more expensively.
- BSX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.52 | ||
| Fwd PE | 25.71 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BSX indicates a somewhat cheap valuation: BSX is cheaper than 71.89% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, BSX is valued a bit cheaper than 77.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.91 | ||
| EV/EBITDA | 28.17 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- BSX has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as BSX's earnings are expected to grow with 16.50% in the coming years.
PEG (NY)1.38
PEG (5Y)3.19
EPS Next 2Y18.12%
EPS Next 3Y16.5%
5. Dividend
5.1 Amount
- No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
90.03
-3.71 (-3.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-22 2025-10-22/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners94.07%
Inst Owner Change0.23%
Ins Owners0.15%
Ins Owner Change-0.4%
Market Cap133.46B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts85.5
Price Target127.2 (41.29%)
Short Float %1.3%
Short Ratio2.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-0.82%
PT rev (3m)0.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.36%
EPS NY rev (1m)0.01%
EPS NY rev (3m)1.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.17%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.52 | ||
| Fwd PE | 25.71 | ||
| P/S | 6.9 | ||
| P/FCF | 34.91 | ||
| P/OCF | 28.86 | ||
| P/B | 5.71 | ||
| P/tB | N/A | ||
| EV/EBITDA | 28.17 |
EPS(TTM)2.95
EY3.28%
EPS(NY)3.5
Fwd EY3.89%
FCF(TTM)2.58
FCFY2.86%
OCF(TTM)3.12
OCFY3.47%
SpS13.05
BVpS15.78
TBVpS-1.34
PEG (NY)1.38
PEG (5Y)3.19
Graham Number32.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.09% | ||
| ROICexc | 8.38% | ||
| ROICexgc | 28.19% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 5.13 |
F-Score6
WACC9.65%
ROIC/WACC0.84
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.13%
EPS Next 2Y18.12%
EPS Next 3Y16.5%
EPS Next 5Y15.06%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.6%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.61%
EBIT Next 3Y20.84%
EBIT Next 5Y17.42%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / BSX FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to BSX.
What is the valuation status for BSX stock?
ChartMill assigns a valuation rating of 5 / 10 to BOSTON SCIENTIFIC CORP (BSX). This can be considered as Fairly Valued.
How profitable is BOSTON SCIENTIFIC CORP (BSX) stock?
BOSTON SCIENTIFIC CORP (BSX) has a profitability rating of 7 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX) is 30.52 and the Price/Book (PB) ratio is 5.71.
Can you provide the expected EPS growth for BSX stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX) is expected to grow by 22.13% in the next year.